Late effects and quality of life of childhood cancer survivors: part 1. Impact of stem cell transplantation.
To examine the late effects and health-related quality of life among childhood cancer survivors (CCS) after stem cell transplantation (SCT), we performed a cross-sectional survey using self-rating questionnaires. The subjects were divided into 3 groups: SCT-treated CCS, CCS treated without SCT, and the general population who matched for age, gender, residential area, and work status with the CCS. We analyzed the questionnaires of 185 CCS and 1,000 control participants. The median ages of CCS at diagnosis and survey were 8 and 22 years, respectively. The mean final heights of male and female participants were significantly lower for SCT-treated CCS than for CCS treated without SCT and the controls. Among the SCT-treated CCS, >40% were underweight (BMI < 18.5). Late effects were observed in 78% of SCT-treated CCS versus 45% of CCS treated without SCT. Multivariate analysis revealed that >15 years' duration after therapy completion (OR 2.95; p = 0.014), solid tumors (4.31; p = 0.040), radiotherapy (2.82; p = 0.009), recurrence (4.22; p = 0.017), and SCT (3.39; p = 0.014) were significant risk factors for late effects. Subjective symptoms were significantly frequent in SCT-treated CCS. Physical dysfunction, psychological stress, and social adaptation problems were observed in >70% of SCT-treated CCS.
Ishida
Yasushi
Y
Department of Pediatrics, St. Luke's International Hospital, 10-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan. yaishida@luke.or.jp
Honda
Misato
M
Ozono
Shuichi
S
Okamura
Jun
J
Asami
Keiko
K
Maeda
Naoko
N
Sakamoto
Naoko
N
Inada
Hiroko
H
Iwai
Tsuyako
T
Kamibeppu
Kiyoko
K
Kakee
Naoko
N
Horibe
Keizo
K
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D011788:Quality of Life; D033581:Stem Cell Transplantation; D011795:Surveys and Questionnaires; D017741:Survivors; D055815:Young Adult
J Clin Oncol. 2009 May 10;27(14):2405-14
19289611
J Clin Endocrinol Metab. 2004 Dec;89(12):5981-6
15579747
Endocr J. 2008 Dec;55(6):1055-63
18719293
Int J Hematol. 2002 Aug;76 Suppl 2:15-28
12430895
Bone Marrow Transplant. 2010 Jan;45(1):79-85
19421172
N Engl J Med. 2006 Oct 12;355(15):1572-82
17035650
Blood. 2003 May 1;101(9):3373-85
12511420
J Clin Oncol. 2009 May 10;27(14):2308-18
19364948
Horm Res. 2008;69(2):65-74
18059086
Bone Marrow Transplant. 2009 Mar;43(6):461-8
18936733
Lancet Oncol. 2010 Apr;11(4):331-8
20117965
Br J Haematol. 2002 Jul;118(1):3-22
12100125
J Pediatr Oncol Nurs. 2007 Mar-Apr;24(2):106-15
17332424
Bone Marrow Transplant. 2007 Apr;39(8):483-90
17334386
Support Care Cancer. 2009 Sep;17(9):1169-75
19139926
Cancer. 2005 Apr 15;103(8):1730-9
15761876
Biol Blood Marrow Transplant. 2006 Feb;12(2):138-51
16443512
Br J Haematol. 2002 Jul;118(1):58-66
12100128
J Clin Oncol. 2009 May 10;27(14):2339-55
19364955
Bone Marrow Transplant. 2005 Jul;36(2):171-6
15937508
Pediatr Blood Cancer. 2008 Jan;50(1):1-8
17668859
Pediatr Blood Cancer. 2008 May;50(5):1018-25
17849473
JAMA. 2007 Jun 27;297(24):2705-15
17595271
Br J Haematol. 2002 Jul;118(1):23-43
12100126
Bone Marrow Transplant. 2008 Jan;41(2):223-7
17922039